Skandinaviska Enskilda Banken AB publ decreased its position in shares of Becton Dickinson and Co (NYSE:BDX) by 3.0% during the third quarter, Holdings Channel reports. The fund owned 45,391 shares of the medical instruments supplier’s stock after selling 1,400 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Becton Dickinson and were worth $11,847,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. Acropolis Investment Management LLC bought a new position in Becton Dickinson and during the third quarter valued at $101,000. Almanack Investment Partners LLC. bought a new position in Becton Dickinson and during the second quarter valued at $105,000. Truvestments Capital LLC bought a new position in Becton Dickinson and during the third quarter valued at $105,000. Bartlett & Co. LLC increased its position in Becton Dickinson and by 2,900.0% during the second quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 435 shares during the last quarter. Finally, Bridgeworth LLC bought a new position in Becton Dickinson and during the second quarter valued at $131,000. Institutional investors and hedge funds own 92.60% of the company’s stock.
In related news, Director Timothy M. Ring sold 42,000 shares of the company’s stock in a transaction dated Wednesday, November 7th. The shares were sold at an average price of $237.07, for a total value of $9,956,940.00. Following the completion of the sale, the director now directly owns 93,688 shares of the company’s stock, valued at $22,210,614.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP James C. Lim sold 5,189 shares of the company’s stock in a transaction dated Thursday, November 8th. The stock was sold at an average price of $242.36, for a total transaction of $1,257,606.04. Following the completion of the sale, the executive vice president now directly owns 13,318 shares of the company’s stock, valued at $3,227,750.48. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.
NYSE BDX opened at $243.26 on Friday. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $63.38 billion, a PE ratio of 22.09, a P/E/G ratio of 1.46 and a beta of 1.19. Becton Dickinson and Co has a 12 month low of $209.91 and a 12 month high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting the Zacks’ consensus estimate of $2.93. The firm had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.36 billion. Becton Dickinson and had a net margin of 1.47% and a return on equity of 13.84%. The business’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same period in the prior year, the business posted $2.40 earnings per share. As a group, equities research analysts anticipate that Becton Dickinson and Co will post 12.2 earnings per share for the current year.
WARNING: “Skandinaviska Enskilda Banken AB publ Has $11.85 Million Holdings in Becton Dickinson and Co (BDX)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.com-unik.info/2018/11/10/skandinaviska-enskilda-banken-ab-publ-has-11-85-million-holdings-in-becton-dickinson-and-co-bdx.html.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Risk Tolerance and Your Investment Decisions
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.